Interview: CrystalGenomics, First Korean Bioventure To ‘Go All The Way’
Executive Summary
After reaching milestones by launching a novel osteoarthritis drug and licensing out an AML candidate to a US partner, CrystalGenomics’ CEO talks to Scrip about what else is in store for the South Korean bioventure in 2017 and beyond.
You may also be interested in...
Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods
Fallout from the withdrawal of Vioxx (rofecoxib) will likely have an impact on post-marketing surveillance methods for COX-2 inhibitors and other drugs
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.